|
Outcome
and Vesting Level
|
||
Portion
of the Award
|
Measure
and Outcome
|
% of
maximum
|
% of
award
|
1/3rd
|
Adjusted Free Cash Flow - For the three-year period, the
Company achieved Adjusted Free Cash Flow calculated in accordance
with the principles for the measure of £12.47bn which is above
the threshold level of £11.48bn.
|
63
|
21
|
1/3rd
|
Total Shareholder Return - For the three years ending 31
December 2017, the Company's Total Shareholder Return ranked
5th, which
is above the threshold vesting level against a comparator group of
10 global pharmaceutical companies including GSK.
|
44
|
14.67
|
1/3rd
|
R&D New Products - For the three-year period, the
Company achieved New Product sales calculated in accordance with
the principles for the measure of £11.266bn, which is above
the maximum vesting level of £7.912bn (the threshold level was
£6.474bn).
|
100
|
33.33
|
|
Total vesting for 2015 award
Lapsed
|
69%
31%
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Ms E Walmsley
|
|
b)
|
Position/status
|
Chief Executive Officer
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary Shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2015
under the Company's 2009 Performance Share Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£0.00
|
91,430
|
||
£0.00
|
47,391
|
||
d)
|
Aggregated
information
Aggregated
volume
Price
|
138,821
£0.00
|
|
e)
|
Date
of the transaction
|
2018-02-15
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr R Connor
|
|
b)
|
Position/status
|
President, Global Manufacturing & Supply
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary Shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2015
under the Company's 2009 Performance Share Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£0.00
|
71,160
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2018-02-15
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr L Debruyne
|
|
b)
|
Position/status
|
President, Global Vaccines
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary Shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2015
under the Company's 2009 Performance Share Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£0.00
|
18,203
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2018-02-15
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr S Dingemans
|
|
b)
|
Position/status
|
Chief Financial Officer
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary Shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2015
under the Company's 2009 Performance Share Plan. These shares
are subject to a two-year holding period to end in
2020.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£0.00
|
154,763
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2018-02-15
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr N Hirons
|
|
b)
|
Position/status
|
SVP, Global Ethics and Compliance
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary Shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature
of the transaction
|
The
number of Ordinary Shares vesting on awards granted in 2015 under
the Company's 2009 Performance Share Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£0.00
|
34,502
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2018-02-15
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr B McNamara
|
|
b)
|
Position/status
|
CEO, GSK Consumer Healthcare
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
GlaxoSmithKline plc American Depositary Shares
('ADSs')
ISIN:
US37733W1053
|
|
b)
|
Nature
of the transaction
|
The number of ADSs vesting on awards granted in 2015 under the
Company's 2009 Performance Share Plan and which were made to
compensate for the value of awards forfeited on completion of the
Joint Venture with Novartis.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
$0.00
|
24,345
|
||
$0.00
|
4,871
|
||
d)
|
Aggregated
information
Aggregated
volume
Price
|
29,216
$0.00
|
|
e)
|
Date
of the transaction
|
2018-02-15
|
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr D Redfern
|
|
b)
|
Position/status
|
Chief Strategy Officer
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary Shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2015
under the Company's 2009 Performance Share Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£0.00
|
56,605
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2018-02-15
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Ms C Thomas
|
|
b)
|
Position/status
|
SVP, Human Resources
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary Shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2015
under the Company's 2009 Performance Share Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£0.00
|
75,473
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2018-02-15
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr P Thomson
|
|
b)
|
Position/status
|
President, Global Affairs
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary Shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2015
under the Company's 2009 Performance Share Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£0.00
|
43,667
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2018-02-15
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr D Troy
|
|
b)
|
Position/status
|
SVP & General Counsel
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
GlaxoSmithKline plc American Depositary Shares
('ADSs')
ISIN:
US37733W1053
|
|
b)
|
Nature
of the transaction
|
The number of ADSs vesting on awards granted in 2015 under the
Company's 2009 Performance Share Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
$0.00
|
66,334
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2018-02-15
|
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Dr P Vallance
|
|
b)
|
Position/status
|
Outgoing President, R&D
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary Shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2015
under the Company's 2009 Performance Share Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£0.00
|
156,984
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2018-02-15
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mrs V Whyte
|
|
b)
|
Position/status
|
Company Secretary
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each 'Ordinary Shares'
ISIN: GB0009252882
|
|
b)
|
Nature
of the transaction
|
The number of Ordinary Shares vesting on awards granted in 2015
under the Company's 2009 Performance Share Plan.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£0.00
|
9,667
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2018-02-15
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: February
16, 2018
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|